Literature DB >> 23977542

Malignant pleural mesothelioma: an epidemiological perspective.

Benjamin M Robinson1.   

Abstract

This paper reviews the aetiology, distribution and projected future incidence of malignant mesothelioma. Asbestos exposure is the most thoroughly established risk factor. Debate continues regarding the relative importance of the different asbestos fibre types and the contribution of Simian virus 40 (SV40). Disease incidence varies markedly within and between countries. The highest annual rates of disease, approximately 30 case per million, are reported in Australia and Great Britain. The risk of disease increases with age and is higher in men. Time from asbestos exposure to disease diagnosis is on average greater than 40 years. Non-occupational asbestos exposures contribute an increasing proportion of disease. With the exception of the United States, incidence continues to increase. In developed countries peak incidence is expected to occur before 2030.

Entities:  

Keywords:  Asbestos; epidemiology; incidence; malignant mesothelioma

Year:  2012        PMID: 23977542      PMCID: PMC3741803          DOI: 10.3978/j.issn.2225-319X.2012.11.04

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  54 in total

1.  Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.

Authors:  I Roushdy-Hammady; J Siegel; S Emri; J R Testa; M Carbone
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

2.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

3.  Malignant pleural mesothelioma: a population-based study of survival.

Authors:  Michael T Milano; Hong Zhang
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

Review 4.  The epidemiology of mesothelioma in historical context.

Authors:  J C McDonald; A D McDonald
Journal:  Eur Respir J       Date:  1996-09       Impact factor: 16.671

Review 5.  Chrysotile as a cause of mesothelioma: an assessment based on epidemiology.

Authors:  Charles M Yarborough
Journal:  Crit Rev Toxicol       Date:  2006-02       Impact factor: 5.635

6.  Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study.

Authors:  M Artvinli; Y I Bariş
Journal:  J Natl Cancer Inst       Date:  1979-07       Impact factor: 13.506

7.  Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas.

Authors:  Dario Mirabelli; Domenica Cavone; Enzo Merler; Valerio Gennaro; Antonio Romanelli; Carolina Mensi; Elisabetta Chellini; Carmela Nicita; Alessandro Marinaccio; Corrado Magnani; Marina Musti
Journal:  Occup Environ Med       Date:  2010-11       Impact factor: 4.402

8.  The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979-1999.

Authors:  A K Hilliard; J K Lovett; C R McGavin
Journal:  Occup Med (Lond)       Date:  2003-05       Impact factor: 1.611

9.  Malignant mesothelioma surveillance: a comparison of ICD 10 mortality data with SEER incidence data in nine areas of the United States.

Authors:  Germania A Pinheiro; Vinicius C S Antao; Ki Moon Bang; Michael D Attfield
Journal:  Int J Occup Environ Health       Date:  2004 Jul-Sep

10.  Global magnitude of reported and unreported mesothelioma.

Authors:  Eun-Kee Park; Ken Takahashi; Tsutomu Hoshuyama; Tsun-Jen Cheng; Vanya Delgermaa; Giang Vinh Le; Tom Sorahan
Journal:  Environ Health Perspect       Date:  2011-04       Impact factor: 9.031

View more
  98 in total

1.  Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.

Authors:  Paul G Werthmann; Gerhard Saltzwedel; Gunver S Kienle
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 2.  Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Authors:  Jordan Dozier; Hua Zheng; Prasad S Adusumilli
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  In vitro experimental models of mesothelioma revisited.

Authors:  Anand Singh; Nathanael Pruett; Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 4.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

5.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

6.  The promise of emerging developments and concepts in mesothelioma.

Authors:  Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2017-06

7.  Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial.

Authors:  Pyng Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

8.  Occupational exposures and lung cancer risk among Minnesota taconite mining workers.

Authors:  Elizabeth M Allen; Bruce H Alexander; Richard F MacLehose; Heather H Nelson; Andrew D Ryan; Gurumurthy Ramachandran; Jeffrey H Mandel
Journal:  Occup Environ Med       Date:  2015-05-14       Impact factor: 4.402

9.  Mesothelioma in Mongolia: case report.

Authors:  Naransukh Damiran; Khishigtogtokh Davaajav; Erdenechimeg Erdenebayar; Burmaa Gomboloi; Arthur L Frank
Journal:  Int J Occup Environ Health       Date:  2015-01-13

10.  Cancer incidence among Minnesota taconite mining industry workers.

Authors:  Elizabeth M Allen; Bruce H Alexander; Richard F MacLehose; Heather H Nelson; Gurumurthy Ramachandran; Jeffrey H Mandel
Journal:  Ann Epidemiol       Date:  2015-08-29       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.